Our first-in-class lead monoclonal antibodies target 4CB-1 or its ligand 4CB-2 and are currently under pre-clinical development. Other potential immuno-oncology targets are at different stages of early development.


Immune-therapy drugs designed to enhance the immune response against cancer (immuno-oncology) are at the forefront of modern Oncology. A few such drugs have shown great promise in different cancer types and have been FDA approved, including antibodies to the immune checkpoints PD-1/PD-L1 and CTLA-4. As part of our efforts towards discovery of novel “immuno-therapy drugs”, we are developing proprietary antibodies against 4CB-1 and 4CB-2. Our lead antibodies are aimed at harnessing a patient’s own immune system to fight cancer efficiently.



Immunotherapies designed to suppress acute dysregulated immune responses are used to fight auto-immune disorders. 4C Biomed has identified novel potential ‘immune-suppressor’ targets.